Compare PDYN & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDYN | TARA |
|---|---|---|
| Founded | 1983 | N/A |
| Country | United States | United States |
| Employees | 70 | N/A |
| Industry | Wholesale Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.2M | 236.1M |
| IPO Year | N/A | 2014 |
| Metric | PDYN | TARA |
|---|---|---|
| Price | $5.62 | $3.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $9.67 | ★ $24.40 |
| AVG Volume (30 Days) | ★ 1.0M | 464.4K |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,948,000.00 |
| Revenue This Year | $384.48 | N/A |
| Revenue Next Year | $63.16 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.14 | $2.97 |
| 52 Week High | $10.73 | $7.82 |
| Indicator | PDYN | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 51.82 | 44.83 |
| Support Level | $4.74 | $3.69 |
| Resistance Level | $6.35 | $4.23 |
| Average True Range (ATR) | 0.32 | 0.16 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 95.43 | 41.74 |
Palladyne AI Corp is a software company focused on autonomy for robotic systems and solutions. Its artificial intelligence and machine learning software seeks to revolutionize the capabilities of robots, enabling them to observe, learn, reason, and act in structured and unstructured environments. AI and ML software platform of the company empowers robots to perceive variations or changes in the real-world environment, enabling them to autonomously maneuver and manipulate objects accurately in response. Palladyne AI software has wide application, including in industries such as automotive, aviation, construction, defense, general manufacturing, infrastructure inspection, logistics and warehousing.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.